BioCentury
ARTICLE | Company News

Innate Pharma, Novo Nordisk deal

May 11, 2009 7:00 AM UTC

Innate disclosed in its 1Q09 earnings that the R&D portion of a 2003 deal granting Novo rights to receptor targets expressed by natural killer (NK) cells expired in March. License rights to the compou...